INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42001, 17028, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42002, 17029, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42003, 17030, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42004, 27849, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42005, 27850, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42006, 27851, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42007, 27852, 'Cytarabine', 'Liver Diseases', 'Cytarabine is extensively metabolized by the liver.  Patients with impaired hepatic function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised hepatic function.  Periodic checks of liver function should be performed in patients receiving Cytarabine Injection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42008, 14350, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42009, 17025, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42010, 17026, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42011, 17027, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42012, 17028, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42013, 17029, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42014, 17030, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42015, 27849, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42016, 27850, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42017, 27851, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42018, 27852, 'Cytarabine', 'Kidney Diseases', 'Cytarabine is primarily eliminated by the kidney.  Patients with impaired renal function may be at increased risk for CNS toxicity during high dose cytarabine therapy.  Therapy with cytarabine should be administered cautiously and the dosages modified in patients with or predisposed to compromised renal function.  Periodic checks of kidney function should be performed in patients receiving Cytarabine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42019, 20833, 'Aliskiren', 'Diabetes Mellitus', 'The use of aliskiren is contraindicated in patients with diabetes who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), as there is an increased risk of renal impairment, hyperkalemia, and hypotension.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42020, 20833, 'Aliskiren', 'Hypotension', 'Symptomatic hypotension may occur after treatment initiation with aliskiren in patients with marked volume depletion, salt depletion, or with combined use of aliskiren and other agents acting on the renin-angiotensin-aldosterone system.  It is recommended to correct the volume or salt depletion before administering aliskiren.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42021, 20833, 'Aliskiren', 'Kidney Diseases', 'Renal function should be monitored periodically in patients treated with aliskiren, as changes can occur including acute renal failure.  Patients on aliskiren whose renal function may depend in part of the RAAS (renin-angiotensin-aldosterone system), such as patients with renal artery stenosis, severe heart failure, or postmyocardial infarction may be at higher risk for developing acute renal failure.  Treatment should be discontinued in any patients who develop clinically significant decrease in renal function.  Patients with renal impairment should be observed closely.  The safety and effectiveness of aliskiren have not been established in patients with severe renal impairment (CrCl < 30 mL/min), as these patients were excluded from clinical trials.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42022, 3278, 'Dacarbazine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42023, 3278, 'Dacarbazine', 'Liver Diseases', 'The pharmacokinetic disposition of dacarbazine may be altered in patients with hepatic impairment.  Hepatotoxicity, including hepatic vein thrombosis and hepatocellular necrosis, have been reported.  Patients should be instructed to immediately report any sign or symptoms of liver dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with dacarbazine should be administered cautiously in patients with or predisposed to compromised hepatic function.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42024, 3278, 'Dacarbazine', 'Bone Marrow Failure Disorders', 'Dacarbazine is myelosuppressive, primarily affecting  leukocytes and thrombocytes, although anemia occasionally occurs.  Deaths due to myelosuppression have been reported.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Therapy with dacarbazine should be withheld or extreme caution exercised when administered in patients whose bone marrow reserve may be severely depressed.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42025, 3278, 'Dacarbazine', 'Kidney Diseases', 'Dacarbazine is partially eliminated by the kidney via renal tubular secretion.  Approximately 40% of dacarbazine is eliminated unchanged in the urine.  The half-life of dacarbazine may be increased in patients with renal impairment.  Rare reports of unspecified, severe renal toxicity has been noted.  Therapy with dacarbazine should be administered cautiously to patients with compromised renal function.  Clinical monitoring of renal function is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42026, 14350, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42027, 17025, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42028, 17026, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42029, 17027, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42030, 17028, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42031, 17029, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42032, 17030, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42033, 27849, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42034, 27850, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42035, 27851, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42036, 27852, 'Cytarabine (liposomal)', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42037, 14350, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42038, 17025, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42039, 17026, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42040, 17027, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42041, 17028, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42042, 17029, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42043, 17030, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42044, 27849, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42045, 27850, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42046, 27851, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42047, 27852, 'Cytarabine (liposomal)', 'Perimeningeal Infections', 'The use of cytarabine liposomal is contraindicated in patients with active meningeal infection.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42048, 14350, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42049, 17025, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42050, 17026, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42051, 17027, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42052, 17028, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42053, 17029, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42054, 17030, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42055, 27849, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42056, 27850, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42057, 27851, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42058, 27852, 'Cytarabine (liposomal)', 'Bone Marrow Failure Disorders', 'Cytarabine is a potent bone marrow suppressant.  Therapy with cytarabine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leucocyte and platelet counts performed daily.  Bone marrow examinations should be performed frequently after blasts have disappeared from the peripheral blood.  Consider suspending or modifying therapy when drug-induced marrow depression has resulted in a platelet count under 50,000 or a polymorphonuclear granulocyte count under 1000/mm3.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42059, 0, 'Dabrafenib', 'Cardiomyopathies', 'Cardiomyopathy/reduction in left ventricular ejection fraction (LVEF) has been reported with the use of dabrafenib.  Exercise caution when using this drug in patients at risk of conditions that could impair left ventricular function.  It is recommended to assess LVEF by echocardiogram or multigated acquisition (MUGA) scan before initiation of therapy, 1 month after, and then at 2- to 3-month intervals while on treatment.  Withhold therapy for symptomatic cardiomyopathy or asymptomatic LV dysfunction of greater than 20% from baseline that is below institutional lower level of normal.  Resume therapy at the same dose level upon recovery of cardiac function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42060, 0, 'Dabrafenib', 'Diabetes Mellitus', 'The use of dabrafenib may cause hyperglycemia in patients with a history of diabetes.  Care should be exercised when using this drug in diabetic patients.  It is recommended to monitor serum glucose levels at the start of therapy and as clinically indicated.  Initiate or optimize anti-hyperglycemic medications as appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42061, 0, 'Dabrafenib', 'Fever', 'Serious febrile reactions and fever of any severity complicated by rigors or chills, hypotension, dehydration, and/or renal failure have been observed with the use of dabrafenib.  The incidence and severity of pyrexia are increased when this drug is administered in combination with trametinib.  Patients with serious non-infectious febrile events responded well to dose interruption and/or dose reduction and supportive care.  It is recommended to withhold therapy for fever of 38.5 degrees Celsius (101.3 degrees Fahrenheit) or higher, for any serious febrile reaction, or fever associated with complications; evaluate for infection.  Consider the administration of antipyretics to resolve fever, and as secondary prophylaxis when resuming therapy for patients with prior episode of severe febrile reaction or fever associated with complications.  For instances in which antipyretics are insufficient, consider administering corticosteroids.  Upon resolution of pyrexia, dose reduction and/or permanent therapy discontinuation may be required.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42062, 0, 'Dabrafenib', 'Glucosephosphate Dehydrogenase Deficiency', 'Dabrafenib contains a sulfonamide moiety.  Care should be exercised when using this drug in patients with glucose-6-phosphate dehydrogenase (G6PD) as it may increase the risk of hemolytic anemia.  It is recommended to monitor patients with G6PD deficiency for signs of hemolytic anemia during therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42063, 0, 'Dabrafenib', 'Hemorrhage', 'The use of dabrafenib may increase the change of hemorrhagic events.  Use care when using this drug in patients at risk of bleeding.  It is recommended to permanently discontinue treatment for all Grade 4 hemorrhagic events and for any Grade 3 hemorrhagic events that do not improve.  Withhold therapy for Grade 3 hemorrhagic events; if improved, resume at the next lower dose level.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42064, 0, 'Dabrafenib', 'Toxic Optic Neuropathy', 'The use of dabrafenib may cause uveitis, including iritis and iridocyclitis.  Care should be exercised when using this agent in patients at risk of ocular toxicities.  During therapy, it is recommended to routinely monitor patients for visual signs and symptoms of uveitis, such as a change in vision, photophobia, and eye pain.  Upon examination, if iritis is diagnosed administer ocular therapy, and continue this drug without a dose modification.  For severe uveitis or iridocyclitis, interrupt therapy and treat as clinically indicated and permanently discontinue treatment for persistent Grade 2 or greater uveitis of 6 weeks or more.  No dose modifications are required if treatment effectively controls ocular inflammation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42065, 0, 'Dabrafenib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42066, 0, 'Dalbavancin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42067, 0, 'Dalbavancin', 'Liver Diseases', 'Therapy with dalbavancin should be administered cautiously in patients with moderate or severe liver dysfunction (Child-Pugh B or C) as no data are available to determine the appropriate dosing in these patients.  No dosage adjustment is recommended for patients with mild liver dysfunction (Child-Pugh A).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42068, 0, 'Dalbavancin', 'Kidney Diseases', 'The recommended regimen for dalbavancin in patients with CrCl less than 30 mL/min who are not receiving regularly scheduled hemodialysis is 1125 mg as a single dose OR 750 mg once, followed by 375 mg one week later.  No dosage adjustment is necessary for patients with CrCl greater than 30 mL/min or for patients receiving regularly scheduled hemodialysis; dalbavancin may be administered without regard to the timing of hemodialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42069, 963, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42070, 3210, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42071, 14087, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42072, 14422, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42073, 25927, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42074, 26491, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42075, 26492, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42076, 26493, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42077, 26494, 'Cyclosporine', 'Hypertension', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with uncontrolled hypertension.  Hypertension, possibly due to renal vasoconstriction, has occurred in 50% of patients receiving cyclosporine.  Antihypertensive therapy may be necessary for kidney, liver, and heart transplant recipients treated with cyclosporine.  Hypertension may decline with continued used, but has persisted in some patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42078, 963, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42079, 3210, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42080, 14087, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42081, 14422, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42082, 25927, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42083, 26491, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42084, 26492, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42085, 26493, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42086, 26494, 'Cyclosporine', 'Kidney Diseases', 'The use of cyclosporine is contraindicated in patients with rheumatoid arthritis or psoriasis with abnormal renal function.  Cyclosporine causes a reversible reduction in renal blood flow and glomerular filtration rate resulting in increased serum creatinine and blood urea nitrogen.  Mild nephrotoxicity generally responds to reductions in cyclosporine doses.  Persistent, chronic, and progressive nephrotoxicity has occurred.  Renal biopsies from these patients can demonstrate interstitial fibrosis, tubular atrophy, global or segmental glomerulosclerosis, or smooth vascular muscle damage.  Larger cumulative doses or elevated cyclosporine trough levels may be associated with the development of interstitial fibrosis.  Clinical monitoring of renal function is necessary and differentiation between cyclosporine-induced nephrotoxicity, allograft rejection, and other causes of impaired renal function should be determined prior to cyclosporine dosage adjustments.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42087, 963, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42088, 3210, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42089, 14087, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42090, 14422, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42091, 25927, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42092, 26491, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42093, 26492, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42094, 26493, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42095, 26494, 'Cyclosporine', 'Liver Diseases', 'Cyclosporine is extensively metabolized by CYP450 3A enzymes in the liver (some GI and renal metabolism) and primarily eliminated in the bile and feces.  Cyclosporine can induce dose-related nephrotoxicity and hepatotoxicity.  Hepatotoxicity, usually noted during the first month of therapy (high dosages) is characterized by elevations of hepatic enzymes and bilirubin.  Reduction in chemistry levels usually results with dosage reduction.  Therapy with cyclosporine should be administered cautiously and dosages modifications considered in patients with or predisposed to hepatic dysfunction.  Clinical monitoring of hepatic function, particularly during administration of high dosages, is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42096, 963, 'Cyclosporine', 'Malabsorption Syndromes', 'Patients with malabsorption syndromes may have difficulty achieving therapeutic serum concentrations with the Sandimmune formulations (capsules or solution) of cyclosporine.  An alternative formulation, Neoral (capsule or solution for microemulsion), has increased bioavailability compared to Sandimmune.  Sandimmune and Neoral are not bioequivalent and should not be used interchangeably without physician supervision.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42097, 3210, 'Cyclosporine', 'Malabsorption Syndromes', 'Patients with malabsorption syndromes may have difficulty achieving therapeutic serum concentrations with the Sandimmune formulations (capsules or solution) of cyclosporine.  An alternative formulation, Neoral (capsule or solution for microemulsion), has increased bioavailability compared to Sandimmune.  Sandimmune and Neoral are not bioequivalent and should not be used interchangeably without physician supervision.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42098, 14087, 'Cyclosporine', 'Malabsorption Syndromes', 'Patients with malabsorption syndromes may have difficulty achieving therapeutic serum concentrations with the Sandimmune formulations (capsules or solution) of cyclosporine.  An alternative formulation, Neoral (capsule or solution for microemulsion), has increased bioavailability compared to Sandimmune.  Sandimmune and Neoral are not bioequivalent and should not be used interchangeably without physician supervision.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42099, 14422, 'Cyclosporine', 'Malabsorption Syndromes', 'Patients with malabsorption syndromes may have difficulty achieving therapeutic serum concentrations with the Sandimmune formulations (capsules or solution) of cyclosporine.  An alternative formulation, Neoral (capsule or solution for microemulsion), has increased bioavailability compared to Sandimmune.  Sandimmune and Neoral are not bioequivalent and should not be used interchangeably without physician supervision.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (42100, 25927, 'Cyclosporine', 'Malabsorption Syndromes', 'Patients with malabsorption syndromes may have difficulty achieving therapeutic serum concentrations with the Sandimmune formulations (capsules or solution) of cyclosporine.  An alternative formulation, Neoral (capsule or solution for microemulsion), has increased bioavailability compared to Sandimmune.  Sandimmune and Neoral are not bioequivalent and should not be used interchangeably without physician supervision.', '2', '', 'DDInter', 0);
